oral semaglutide glycemic impact

A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for

Semaglutide vs Tirzepatide: Glycemic Control Showdown

Semaglutide vs Tirzepatide: Glycemic Control Showdown In the OASIS trial, 352 adults without diabetes took semaglutide and tirzepatide, and both drugs lowered average fasting glucose by about 5 mg/dL while preserving insulin sensitivity. Weight loss shouldn’t mean dropping insulin control, and the data show that Wegovy actually preserves